Supergenics Stock

03033

MYL03033O007

Biotechnology & Medical Research

Market Closed - BURSA MALAYSIA 11:50:01 30/12/2025 +03			5-day change	1st Jan Change
0.2500 ^MYR	+21.95%		-.--%	-

08-28	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-30	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI

Supergenics Berhad is a Malaysia-based management and investment holding company. The Company operates through three segments: Integrated Turnkey Solutions, Biomedical, and Investment Holding. Its Integrated Turnkey Solutions segment is engaged in the provision of integrated turnkey solutions for the related development of cleanrooms and the provision of related maintenance services. Its Biomedical segment is engaged in the provision of administrative health care services, operating medical laboratories, and developing regenerative wellness products. The Company provides laboratory services, including storage and handling of stem cell samples. Its services include stem cells, mesenchymal stem cells (MSC), natural killer (NK) cells, exosomes, and MSC exosomes. Its subsidiaries include Supergenics Solution Sdn. Bhd., Supergenics Life Science Sdn. Bhd., Supergenics Therapeutic Sdn. Bhd., Supergenics Bio Agro Sdn. Bhd., Supergenics Stembank Sdn. Bhd., and Supergenics Global Sdn. Bhd.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
03033 Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	29.11M 7.17M 6.42M 5.92M 5.36M 10.03M 683M 10.19M 70.69M 28.2M 357M 26.91M 26.34M 1.13B	P/E 2024	-9.45x	P/E 2025	-8.61x
Enterprise Value	32.5M 8.01M 7.17M 6.62M 5.99M 11.19M 762M 11.38M 78.93M 31.49M 399M 30.05M 29.41M 1.26B	EV / Sales 2024	13.9x	EV / Sales 2025	5.78x
Free-Float	41.6%	Yield 2024 *	-	Yield 2025	-

08-28	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-30	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
02-27	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-05	Supergenics Seeks 6-Month Extension to Complete Private Placement of Shares	MT
29/08/25	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/08/25	Supergenics fixes issue price at 0.27 RGT per share	RE
12/08/25	Supergenics Berhad Announces the Redesignation of Lau Meng Hong from Executive Director to Non Independent and Non Executive Director, Effective August 12, 2025	CI
21/03/25	Supergenics Berhad Announces Change of Registered Office Address	CI
28/02/25	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2024	CI
30/08/24	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/04/24	Supergenics Seeks More Time to Complete Private Share Placement	MT
29/02/24	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/02/24	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI

1 year	0.25	0.25
3 years	0.15	0.6
5 years	0.15	0.6
10 years	0.15	0.6

Manager	Title	Age	Since
Bii Chau Tan CEO	Chief Executive Officer	48	24/04/2019
Yuet Chyn Wong SEC	Corporate Secretary	-	02/06/2022

Director	Title	Age	Since
Bii Chau Tan BRD	Director/Board Member	48	24/04/2019
Fun Kim Ng BRD	Director/Board Member	60	24/04/2019
Kiat Yang Chan BRD	Director/Board Member	46	28/01/2022

Supergenics Stock

Stocks

03033

MYL03033O007

Biotechnology & Medical Research

Valuation: Supergenics

Chart: Supergenics

Latest news: Supergenics

Quotes and Performance

Price Extremes

Managers and Directors: Supergenics

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUPERGENICS	+21.95%	-.--%	+21.95%	+8.70%	7.17M
WUXI APPTEC CO., LTD.	-0.62%	+0.50%	+33.92%	+60.07%	64.38B
ARGENX SE	+0.70%	+3.66%	+15.43%	+85.37%	56.16B
LONZA GROUP AG	+0.37%	+1.80%	+15.19%	+106.48%	54.16B
IQVIA HOLDINGS INC.	-3.28%	-4.69%	+23.01%	+50.30%	45.33B
BEONE MEDICINES AG	+0.30%	-1.47%	+20.71%	+99.38%	42.25B
REVOLUTION MEDICINES, INC.	-1.10%	+0.79%	+220.14%	+927.06%	40.78B
GENMAB A/S	+3.27%	+47.69%	+112.29%	+96.13%	33.8B
CELLTRION, INC.	+1.22%	-1.39%	+13.92%	+46.95%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.29%	-1.72%	+21.00%	-6.85%	23.57B
Average	+2.17%	+4.25%	+49.76%	+147.36%	39.27B
Weighted average by Cap.	-0.09%	+3.64%	+49.68%	+161.24%

	2024	2025
Net sales	5.32M 1.31M 1.17M 1.08M 980K 1.83M 125M 1.86M 12.92M 5.16M 65.33M 4.92M 4.81M 207M	5.63M 1.39M 1.24M 1.15M 1.04M 1.94M 132M 1.97M 13.66M 5.45M 69.06M 5.2M 5.09M 219M
Net income	-7.28M -1.79M -1.61M -1.48M -1.34M -2.51M -171M -2.55M -17.68M -7.05M -89.38M -6.73M -6.59M -283M	-3.37M -829K -743K -685K -620K -1.16M -78.95M -1.18M -8.17M -3.26M -41.32M -3.11M -3.05M -131M
Net Debt	4.48M 1.1M 988K 911K 825K 1.54M 105M 1.57M 10.87M 4.34M 54.96M 4.14M 4.05M 174M	3.39M 836K 749K 691K 625K 1.17M 79.62M 1.19M 8.24M 3.29M 41.67M 3.14M 3.07M 132M